Lucid Diagnostics' ENVET-BE Clinical Utility Study Of EsoGuard Esophageal Precancer Testing Accepted For Peer-Reviewed Publication; Study Confirms Clinical Utility Of EsoGuard As A Non-Invasive Triage Tool To Significantly Increase Yield Of Invasive Upper Endoscopy

Author: Benzinga Newsdesk | March 18, 2025 07:34am

Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy

NEW YORK, March 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that its ENVET-BE clinical utility study has been accepted for publication in Gastroenterology & Hepatology—the fifth peer-reviewed publication of clinical utility data for Lucid's EsoGuard® Esophageal DNA Test, and the second to present findings from a real-world screening population. The manuscript, entitled Enhancing the Diagnostic Yield of EGD for Diagnosis of Barrett's Esophagus Through Methylated DNA Biomarker Triage, demonstrates that confirmatory upper endoscopy (EGD) performed in EsoGuard-positive patients had a substantially higher diagnostic yield for detecting esophageal precancer (Barrett's Esophagus or BE) than the expected yield of screening EGD alone in at-risk patients.

Posted In: LUCD PAVM